Abstract
Clinicopathological Analysis of Rectal Cancer after Neoadjuvant Chemotherapy
Satoko Morohashi*
Corresponding Author: Satoko Morohashi, Hirosaki Municipal Hospital, Japan
Accepted: November 01, 2019
Citation: Morohashi S. (2019) Clinicopathological Analysis of Rectal Cancer after Neoadjuvant Chemotherapy. BioMed Res J, 3(S1): 23.
Copyrights: ©2019 Morohashi S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :

Neoadjuvant chemotherapy (NAC) of rectal cancer has some advantages: 1) Whole body control from the early stage of treatment; 2) Tumor reduction (favorable for laparoscopic surgery); 3) No functional failure due to radiation.

In this study, a total of 50 patients with rectal cancer, treated with NAC, were examined. The pathological primary cancer area and the radiological cancer volume reduction ratio were measured using CT and/or MRI imaging and the donut-shaped measurement method. Immunostaining of cytokeratin AE1/AE3 was performed to quantitatively measure the cancer cell mass in the largest section of rectal cancer. Cytokeratin AE1/AE3-stained area (P=0.04), mitosis (P=0.0027) and radiological donut-shaped images after NAC (P=0.010) were lower in the high radiological cancer volume reduction ratio group compared with the low radiological cancer volume reduction ratio group.